A comparison of fluticasone propionate (FP) and mometasone furoate (MF) nasal spray in the treatment of nasal polyposis associated with asthma

M. D. Filipovic, S. S. Cekic (Nis, Serbia And Montenegro)

Source: Annual Congress 2006 - Recent advances in asthma treatment
Session: Recent advances in asthma treatment
Session type: Poster Discussion
Number: 1804
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. D. Filipovic, S. S. Cekic (Nis, Serbia And Montenegro). A comparison of fluticasone propionate (FP) and mometasone furoate (MF) nasal spray in the treatment of nasal polyposis associated with asthma. Eur Respir J 2006; 28: Suppl. 50, 1804

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Higher cellular retention and activity after pulse exposure by budesonide (BUD) than fluticasone propionate (FP) and mometasone furoate (MF)
Source: Eur Respir J 2001; 18: Suppl. 33, 158s
Year: 2001

Evaluation of fluticasone (flixonase) nasal spray versus beclomethasone (beconase) nasal spray in the treatment of allergic rhinitis
Source: Eur Respir J 2004; 24: Suppl. 48, 124s
Year: 2004

Variable lipophilicity of budesonide: Comparison with fluticasone propionate, mometasone furoate, and ciclesonide
Source: Eur Respir J 2003; 22: Suppl. 45, 33s
Year: 2003

Clinical efficacy of once-daily mometasone furoate in children with persistent asthma switched from treatment with fluticasone propionate
Source: Annual Congress 2011 - Airways disease comorbidities and general aspects
Year: 2011

A comparison of the efficacy of beclomethasone dipropionate (BDP) and fluticasone propionate (FP) aqueous nasal spray on symptoms and quality of life in perennial allergic rhinitis
Source: Eur Respir J 2003; 22: Suppl. 45, 110s
Year: 2003

Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma
Source: Eur Respir J 2014; 43: 773-782
Year: 2014



Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) compared with fluticasone propionate/salmeterol combination (FP/SAL) in adults and adolescents with persistent asthma
Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma
Year: 2012

A superior improvement in lung function in patients with moderate persistent asthma is seen with mometasone furoate 200 μg b.i.d delivered by dry powder inhaler compared with beclomethasone dipropionate 168 μg
Source: Eur Respir J 2001; 18: Suppl. 33, 96s
Year: 2001

Once-daily versus twice-daily administration of mometasone furoate dry powder inhaler (MF-DPI) improves lung function in children with asthma previously maintained on inhaled corticosteroids (ICS)
Source: Eur Respir J 2004; 24: Suppl. 48, 164s
Year: 2004

Seasonality of asthma exacerbations: efficacy of fluticasone furoate/vilanterol 100/25µg (FF/VI) vs fluticasone furoate 100µg (FF) alone
Source: International Congress 2017 – Asthma management
Year: 2017


Late Breaking Abstract - Dose responses for topical efficacy and systemic activity, dose equivalence and relative therapeutic index for fluticasone furoate (FF), fluticasone propionate (FP) and budesonide (BUD) in asthmatic subjects.
Source: International Congress 2019 – New towards old therapies in airway diseases
Year: 2019



Fluticasone furoate (FF), a novel inhaled corticosteroid (ICS), demonstrates once-daily (OD) efficacy in asthma when dosed in the evening
Source: Annual Congress 2010 - New treatments for asthma and COPD
Year: 2010

A comparison of oral loratadine and fluticasone propionate aqueous nasal spray plus oral loratadine in the treatment of atopic cough associated with seasonal allergic rhinitis (SAR)
Source: Eur Respir J 2005; 26: Suppl. 49, 136s
Year: 2005

Mometasone furoate nasal spray compared with loradatine in school children with seasonal allergic rhinitis
Source: Annual Congress 2010 - Managing asthma and allergic disease in children
Year: 2010

Mometasone furoate is a less specific glucocorticoid than fluticasone propionate
Source: Eur Respir J 2002; 20: 1386-1392
Year: 2002



Administration of mometasone furoate once daily in the evening is as effective as mometasone furoate administered twice daily in improving lung function in patients with mild to moderate persistent asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 33s
Year: 2003

Fluticasone furoate (FF): Prolonged duration of action compared with other ICS
Source: Annual Congress 2010 - Regulation of airway pharmacology
Year: 2010

Mometasone furoate delivered via Breezhaler and Twisthaler in patients with asthma
Source: International Congress 2019 – Asthma: outcomes of clinical trials and cohorts
Year: 2019


Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma
Source: Annual Congress 2012 - Asthma treatment: efficacy and safety
Year: 2012

Assessment of the defined daily dose for mometasone furoate dry powder inhaler in persistent asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 33s
Year: 2003